Fangsheng Pharmaceutical: Clinical trial for gynecological hemostatic and analgesic granules approved
I'm PortAI, I can summarize articles.
According to the Zhitong Finance APP, Fangsheng Pharmaceutical announced that its holding subsidiary, Guangdong Fangsheng Rongo Pharmaceutical Co., Ltd. (referred to as "Fangsheng Rongo"), has received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration for its innovative traditional Chinese medicine research and development project, gynecological hemostatic and analgesic granules. The National Medical Products Administration has agreed to conduct Phase II and III clinical trials based on further improvement of the clinical trial protocol
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments